Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683713 | 0.78 | AR (1.00) | ARPGR | |
| SCHEMBL14409341 | 0.72 | AR (0.64) | ARPGR | |
| SCHEMBL19603965 | 0.67 | PGR (0.62) | ARPGR | |
| SCHEMBL1770722 | 0.64 | AR (0.55) | AR | |
| SCHEMBL1771247 | 0.64 | AR (0.55) | ARPGR | |
| SCHEMBL1772458 | 0.64 | GSK3B (0.45) | — | |
| SCHEMBL10838748 | 0.63 | PGR (0.47) | ARPGR | |
| SCHEMBL1772676 | 0.61 | AR (0.61) | AR | |
| SCHEMBL1771342 | 0.61 | AR (0.42) | AR | |
| SCHEMBL1772197 | 0.60 | AR (0.62) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-04-22 | — | — | US | disclosed |
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3527210-A1 | COMPOSITION, APPLICATION THEREOF AND TREATMENT METHOD | Kangpu Biopharmaceuticals, Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3357513-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9205102-B2 | Method for treatment of castration-resistant prostate cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-12-08 | — | — | US | disclosed |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-11 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | CYP21A2, CYP17A1, NR5A1 | AR 5/4885PGR 96/4885 |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | AR, NR5A1, CYP17A1 | AR 1/4885PGR 186/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | AR 1818/4885PGR 1096/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | AR 5/4885PGR 96/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | AR 2420/4885PGR 2085/4885 |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | IGFBP5, IGFBP2, IGFBP1 | AR 7/4885PGR 414/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | AR 1853/4885PGR 2094/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | AR 1207/4885PGR 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.